Published by TMR Research Insights
Posted on August 27, 2021
4 min readLast updated: February 14, 2026
Add as preferred source on Google
The increasing prevalence of cancer across the world has influenced a number of markets. An important one among those is the global cancer immunotherapy market. According to Transparency Market Research (TMR), a leading market research and intelligence firm, the opportunity in the global cancer immunotherapy market will rise at a solid CAGR of 14.60% during the period from 2016 to 2024.
In terms of therapies, monoclonal antibodies have been registering the most prominent demand so far. The affordability of this therapy has given it an upper hand over other types of therapies. Its high popularity will continue to attract significant demand in the near future, keeping this segment on the top most position. On the other hand, the demand for immune checkpoint inhibitors is also expected to rise over the next few years due to its greater success rate and superior efficacy.
Request Brochure of Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4312
Cancer immunotherapy finds extensive utilization in the treatment of prostate cancer, blood cancer, melanoma, lung cancer, breast cancer, colorectal cancer, and several other chronic diseases. Among these, the demand for immunotherapy is relatively higher in the breast cancer segment.
Lung cancer is also presenting a considerable increase in the rate of demand for immunotherapy. The rising population base of smokers and the alarming increase in air pollution in urban areas are the main factors behind this, states the research report.
Cancer Immunotherapy Reports High Demand
The global cancer immunotherapy market is reporting a tremendous rise, thanks to a number of factors. Some of the important factors that are supporting this market significantly are:
All these factors are propelling the global cancer immunotherapy market. Although the future of this market looks bright, it may face challenges from strict government regulations in the near future. The absence of appropriate infrastructure for cancer diagnosis and screening in emerging nations is also expected to hinder this market in the years to come, reports the research study.
Request for Analysis of COVID-19 Impact on Cancer Immunotherapy Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=4312
Europe and North America to continue to Lead
Geographically, the worldwide cancer immunotherapy market is segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. Europe and North America have been leading this market since long. The presence of superior medical and healthcare infrastructure is supporting both the regional markets.
The ongoing research activities for the development of innovative therapies for cancer treatment are likely to aid these markets in the coming years, resulting in their continued dominance. With ample of untapped opportunities, Asia Pacific is also expected to report a promising growth in the near future, notes the market study.
Buy Cancer Immunotherapy Market Report – https://www.transparencymarketresearch.com/checkout.php?rep_id=4312<ype=S
The leading players in the global cancer immunotherapy market are Amgen Inc., AstraZeneca Plc., Bristol-Myers Squibb Co., GlaxoSmithKline Plc., F. Hoffmann-La Roche Ltd., Eli Lilly and Co., Sanofi, Merck & Co. Inc., Janssen Biotech Inc., Pfizer Inc., Novartis AG, Spectrum Pharmaceuticals Inc., and Takeda Pharmaceuticals.
More Trending Reports by Transparency Market Research –
Surgical Robots Market: https://www.prnewswire.com/news-releases/surgical-robots-market-to-reach-us13-1-bn-by-2027-as-acceptance-jumps-high-in-emerging-regions-tmr-study-300997542.html
Surgical Equipment Market: https://www.prnewswire.com/news-releases/global-surgical-equipment-market-to-grow-alongside-advancements-in-healthcare-facilities-across-hospitals-and-healthcare-units-says-tmr-301200087.html
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals. Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information, we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact
Transparency Market Research
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Blog: https://tmrblog.com/
Follow Us: Twitter | LinkedIn
Press Release Source: https://www.transparencymarketresearch.com/pressrelease/cancer-immunotherapy-market.htm
The cancer immunotherapy market is expected to witness a CAGR of 14.6% from 2016 to 2024.
Monoclonal antibodies have been registering the most prominent demand in cancer immunotherapy due to their affordability and effectiveness.
Europe and North America are currently leading the global cancer immunotherapy market, supported by ongoing research and development activities.
The market may face challenges from strict government regulations in the near future, which could impact its growth.
Leading players include Amgen Inc., AstraZeneca Plc., Bristol-Myers Squibb Co., and GlaxoSmithKline Plc., among others.
Explore more articles in the Research Reports category
